AMGN · News · 20260807N
Guidance and Outlook
AMGEN INC · 2026-08-07 · Importance 69 · Surprise 60 · In source text
Amgen raised its full-year 2026 revenue outlook to $38.2 billion-$39.4 billion. Management also raised adjusted EPS guidance to $22.30-$23.50 after strong first-half product performance. The guidance increase followed second-quarter revenue of $10.05 billion, which exceeded the FactSet estimate of $9.43 billion. The company maintained its growth strategy despite approximately $7 billion of loss-of-exclusivity headwinds and biosimilar competition affecting older franchises.
Key facts
- Amgen revised 2026 adjusted EPS guidance to a range of $22.30–$23.50, as reported in filings and coverage. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | positive | committed | — | Amgen revised 2026 adjusted EPS guidance to a range of $22.30–$23.50, as reported in filings and coverage. |